• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Equillium Inc.

    2/14/22 11:57:43 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQ alert in real time by email
    SC 13G 1 tm226449d5_sc13g.htm SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. ________)*

     

    Equillium Inc. 

    (Name of Issuer)

     

    Common Stock, $0.0001 Par Value 

    (Title of Class of Securities) 

     

    29446K106 

    (CUSIP Number)

     

    Laura Tse

    3000 Sand Hill Road, Building 2, Suite 110

    Menlo Park, CA 94025, USA

    650-233-0688

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    December 31, 2021 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    þ Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 29446K106 13G Page 2 of 5 Pages

     

    1.  

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Decheng Capital Management III (Cayman), LLC

    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨
    3.   SEC USE ONLY
     
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5.   SOLE VOTING POWER
     
    4,447,308
      6.   SHARED VOTING POWER
     
    4,447,308
      7.   SOLE DISPOSITIVE POWER
     
    4,447,308
      8.   SHARED DISPOSITIVE POWER
     
    4,447,308

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,447,308

    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨
    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    15.13%

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    IA 

     

     

     

     

    CUSIP No. 29446K106 13G Page 3 of 5 Pages

     

    Item 1.

     

      (a) Name of Issuer
    Equillium Inc.

     

      (b) Address of Issuer’s Principal Executive Offices
    2223 Avenida De La Playa, Suite 105, La Jolla, California 92037, USA

     

    Item 2.

     

      (a) Name of Person Filing
    Laura Tse
         
      (b) Address of the Principal Office or, if none, residence
    3000 Sand Hill Road, Building 2, Suite 110, Menlo Park, CA 94025, USA
         
      (c) Citizenship
    U.S.
         
      (d) Title of Class of Securities
    Common Stock, $0.0001 Par Value
         
      (e) CUSIP Number
    29446K106

     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) þ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    CUSIP No. 29446K106 13G Page 4 of 5 Pages

     

    Item 4.  Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:  4,447,308
             
      (b)   Percent of class:  15.13%
             
      (c)   Number of shares as to which the person has:  
             
          (i) Sole power to vote or to direct the vote 4,447,308
             
          (ii) Shared power to vote or to direct the vote 4,708,288
             
          (iii) Sole power to dispose or to direct the disposition of 4,447,308
             
          (iv) Shared power to dispose or to direct the disposition of 4,447,308

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5.  Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     ¨.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

     

    None/Not Applicable

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    None/Not Applicable

     

    Item 8.  Identification and Classification of Members of the Group.

     

    None/Not Applicable

     

    Item 9.  Notice of Dissolution of Group.

     

    None/Not Applicable

     

     

     

     

    CUSIP No. 29446K106 13G Page 5 of 5 Pages

     

    Item 10.  Certification.

     

      (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
           
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
           
      (b)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
           
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      2/14/2022 
      Date
       
      /s/ Laura Tse   
      Signature
       
      Chief Compliance Officer   
      Name/Title

     

     

    Get the next $EQ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EQ

    DatePrice TargetRatingAnalyst
    3/28/2025$3.00 → $1.00Outperform → Market Perform
    Leerink Partners
    1/5/2022$18.00 → $14.00Outperform
    SVB Leerink
    10/29/2021$12.00Buy
    Stifel
    9/15/2021$14.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EQ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

      EQ504 protects against gut damage in a mouse model of ulcerative colitis EQ504 increases Treg stability and function while suppressing pathogenic Th17 responses EQ504 promotes healing of intestinal epithelial cells by promoting anti-inflammatory cytokines Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7. "Decades of independent re

      5/6/25 8:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

      EQ504 targets the aryl hydrocarbon receptor, a clinically validated pathway in the treatment of both skin and gastrointestinal diseases EQ504 has a unique, multi-modal, non-immunosuppressive mechanism of action that is complementary to other immuno-inflammatory therapeutics EQ504 data to be presented in three poster presentations next week at the annual meeting of the American Association of Immunologists (AAI) Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced the advancement of a novel and potent aryl hydrocarbon receptor

      5/1/25 8:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Announces Feedback from the U.S. Food and Drug Administration

      Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that the company has received feedback from its Type D meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for Accelerated Approval, as well as the company's filing for Breakthrough Therapy designation for itolizumab for first-line treatment of acute graft-versus-host disease (aGVHD). The FDA declined to grant Breakthrough Therapy designation or support an Accelerated Approval pathway based on the EQUATOR study data. The FDA highlighted

      4/24/25 9:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care